Latest Breaking News On - Late breaking - Page 1 : vimarsana.com

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Castin' 'n Catchin' fundraiser kicks off in North Alabama

Hundreds of anglers participated in the Castin' 'n Catchin' tournament in Scottsboro, Alabama, with the aim of raising funds for children suffering from heart issues.

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024…

Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

SEATTLE--(BUSINESS WIRE)--Apr 10, 2024--

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

ROOT, Switzerland--(BUSINESS WIRE)--Mar 11, 2024--

Discussing New Phase 2 Findings on Lutikizumab for Hidradenitis Suppurativa with Alexa Kimball, MD, MPH

Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.

AlzeCure Pharma: AlzeCure Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference

Afimetoran Shown to be Safe, Well-Tolerated for Patients with Cutaneous Lupus Erythematosus

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with CLE.

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting® 2023 -November 10, 2023 at 08:58 am EST

Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due...

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs